Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hype...
Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia
About this item
Full title
Author / Creator
Publisher
Berlin: Walter de Gruyter GmbH
Journal title
Language
English
Formats
Publication information
Publisher
Berlin: Walter de Gruyter GmbH
Subjects
More information
Scope and Contents
Contents
Tamsulosin is a first-line drug for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Despite its high ratings for efficacy and safety, these parameters may vary due to genetic polymorphisms of CYP2D6 enzyme, which is involved in the metabolism of the drug. This variability may have great impac...
Alternative Titles
Full title
Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2909071526
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2909071526
Other Identifiers
ISSN
0792-5077
E-ISSN
2191-0162
DOI
10.1515/dmpt-2023-0050
